Literature DB >> 11397862

Persistence of macroprolactinemia due to antiprolactin autoantibody before, during, and after pregnancy in a woman with systemic lupus erythematosus.

A Leaños-Miranda1, D Pascoe-Lira, K A Chávez-Rueda, F Blanco-Favela.   

Abstract

A woman with systemic lupus erythematosus (SLE) with marked increases in circulating 150-kDa PRL was studied from before conception, throughout pregnancy, and after pregnancy. The clinical features of the patient included idiopathic hyperprolactinemia without clinical symptoms such as amenorrhea and galactorrhea before pregnancy. No clinical lupus activity was present during follow-up. Serum PRL increase during pregnancy in this patient was considerably higher at weeks 27 and 33 than in normal pregnant women. In contrast, serum-free PRL levels were considerably lower at weeks 20, 27, and 33 than in normal pregnant women. A 150-kDa PRL (big big PRL) species persisted as the predominant circulating form of PRL throughout each measurement in this woman with SLE. In contrast, the predominant form of PRL in serum from healthy pregnant women was little PRL (or monomeric PRL). The nature of big big PRL was due to the presence of anti-PRL autoantibodies forming an IgG-23 kDa PRL complex, in accordance with the studies by affinity chromatography for IgG and Western blot analysis. The IgG-PRL complex was fully bioactive in vitro (Nb2 rat lymphoma cell assay). Injection of the serum into the rats demonstrated that the IgG-PRL complex was cleared more slowly than serum containing predominantly monomeric PRL. The data suggest that the IgG-PRL complex has biological activity; the absence of symptoms in this woman may be attributed to the fact that due to its large molecular weight, big big PRL does not easily cross the capillary walls. Delayed clearance may account for increased serum PRL levels in this SLE patient with anti-PRL autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397862     DOI: 10.1210/jcem.86.6.7598

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

Review 2.  Prolactin and autoimmunity.

Authors:  Annamaria De Bellis; Antonio Bizzarro; Rosario Pivonello; Gaetano Lombardi; Antonio Bellastella
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

4.  Antiprolactin autoantibodies are associated with hyperprolactinemic status in men infected with human immunodeficiency virus.

Authors:  Alfredo Leaños-Miranda; Iris Contreras-Hernández
Journal:  Endocrine       Date:  2002-11       Impact factor: 3.925

5.  Increased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and increased numbers of transitional-1 B cells after prolactin treatment.

Authors:  Yadira Ledesma-Soto; Francisco Blanco-Favela; Ezequiel M Fuentes-Pananá; Emiliano Tesoro-Cruz; Rafael Hernández-González; Lourdes Arriaga-Pizano; María V Legorreta-Haquet; Eduardo Montoya-Diaz; Luis Chávez-Sánchez; María E Castro-Mussot; Adriana K Chávez-Rueda
Journal:  BMC Immunol       Date:  2012-03-09       Impact factor: 3.615

6.  Prolactin levels correlate with abnormal B cell maturation in MRL and MRL/lpr mouse models of systemic lupus erythematosus-like disease.

Authors:  Maria Victoria Legorreta-Haquet; Rocio Flores-Fernández; Francisco Blanco-Favela; Ezequiel M Fuentes-Pananá; Luis Chávez-Sánchez; Rafael Hernández-González; Emiliano Tesoro-Cruz; Lourdes Arriaga-Pizano; Adriana Karina Chávez-Rueda
Journal:  Clin Dev Immunol       Date:  2013-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.